Meeting
2022 ASCO Annual Meeting
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.
Authors
Xiaojing Xu
Department of Oncology, Cancer center, Zhongshan Hospital, Fudan University, Shanghai, China
Xiaojing Xu , Yiyi Yu , Yan Wang , Yuehong Cui , Wei Li , Li Liang , Qian Li , Shan Yu , Yi Feng , Qing Liu , Pengfei Zhang , Minzhi Lv , Tianshu Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT05143099
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3566)
DOI
10.1200/JCO.2022.40.16_suppl.3566
Abstract #
3566
Poster Bd #
360
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: A phase II, single-arm study.
First Author: Xiaojing Xu
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2022 ASCO Annual Meeting
Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.
First Author: Christine Megerdichian Parseghian
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill